Anteo Diagnostics Acquires DIAsource ImmunoAssays SA
August 26, 2015
Anteo Diagnostics will acquire 100% of DIAsource ImmunoAssays SA for EUR15.4m (with a two-year vendor earn-out), expanding Anteo's product range, manufacturing capabilities and global distribution. DIAsource, headquartered in Louvain-la-Neuve, Belgium, reported EUR11.9m revenue in 2014 (EUR7.2m in H1 2015) and the combined business will total about 100 personnel; the deal is subject to financing and regulatory approvals.
- Buyers
- Anteo Diagnostics
- Targets
- DIAsource ImmunoAssays SA
- Industry
- Medical Devices
- Location
- Walloon Brabant, Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Fremman Capital Acquires Majority Stake in DIESSE Diagnostica Senese
January 27, 2025
Medical Devices
Fremman Capital has acquired a majority stake in Italian In Vitro Diagnostics (IVD) company DIESSE Diagnostica Senese from ARCHIMED's MED II. DIESSE, headquartered in Monteriggioni (Siena), Italy, operates a new biotech campus and ~230 employees and will continue to be led by its management team which retains a meaningful minority stake; Fremman plans to further internationalize and grow the business.
-
Biosynth Carbosynth Acquires Aalto Bio Reagents
May 26, 2022
Biotechnology
Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.
-
bioMérieux Acquires Specific Diagnostics
April 12, 2022
Medical Devices
bioMérieux has agreed to acquire Specific Diagnostics, a U.S.-based developer of the SPECIFIC REVEAL Rapid AST system, to strengthen its sepsis and antimicrobial stewardship portfolio. bioMérieux will acquire 100% of Specific Diagnostics for a consideration equivalent to 3.3% of bioMérieux's market capitalization as of April 11, 2022, paid in cash and newly issued shares; the deal was expected to close by the end of Q2 2022 subject to regulatory approvals.
-
BBI Group Acquires DIARECT AG
June 3, 2020
Medical Devices
BBI Group has acquired DIARECT AG, a Freiburg-based supplier of recombinant autoimmune antigen products, integrating DIARECT's manufacturing facility to establish a centre of excellence for recombinant antigen development. The deal expands BBI's immunoassay reagent portfolio and capabilities, enabling the combined company to pursue high-growth disease segments and broaden DIARECT's geographic reach through BBI's larger sales organization.
-
ARCHIMED (via Duomodiag) Acquires DIESSE Diagnostica Senese SpA
May 13, 2019
Medical Devices
ARCHIMED, through its MED II-backed holding company Duomodiag Sarl, acquired Italian in vitro diagnostics specialist DIESSE Diagnostica Senese SpA in a cross-border carve-out completed on May 13, 2019. The deal — financed by MPS Capital Services and BPER — purchased DIESSE from its founders and Orphée SA (the Swiss subsidiary of the PZ Cormay group) to accelerate product innovation and expand market penetration internationally.
-
Eurogentec S.A. Acquires AnaSpec Inc.
October 26, 2009
Biotechnology
Eurogentec S.A. has signed a definitive agreement to acquire AnaSpec Inc., a Fremont, California-based proteomics company that provides peptides, labeled peptides, fluorescent dyes and assay kits for research and diagnostics. The acquisition expands Eurogentec's genomics and proteomics capabilities and strengthens its geographic presence in the United States, while AnaSpec's founders and senior management will remain with the business.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.